Products

Description

Insulin resistance and insulin secretion are the two main pathophysiological defects in Type 2 diabetes and it is often difficult to determine the underlying cause. However, when the patient is diagnosed with Type 2 diabetes, his first phase insulin secretion is impaired and there is tremendous load on the beta cells, which may lead to beta cell failure. At this stage, it is very important to preserve the precious beta cells by supplementing the patient with an insulin secretagogue in combination with an insulin sensitizer like Pioglitazone.

Moreover, nearly one third of diabetics suffer from nephropathy and in such cases, there is a need of combination that can be safely prescribed even to the renally impaired diabetics. Pioglitazone and Glimepiride combination, which is excreted through dual mechanism. i.e. kidney (urine) and bile (feces), becomes an ideal combination in such cases.

Thus, POZITIV-G™ imparts one of the unique treatment options for diabetics with mild to moderate renal dysfunction.

The combination of both these anti-diabetic agents improves glycaemic control, insulin sensitivity and beta cell function more effectively than treatment with Pioglitazone or Glimepiride alone. It is also proved that this combination improves lipid profile to overcome cardiovascular complications.

POZITIV-G1^® / POZITIV-G2^® TABLETS

(ORAL ANTI-HYPERGLYCEMIC AGENT)

Composition

POZITIV-G 1™

Each uncoated tablet contains:
Pioglitazone Hydrochloride I.P.
equivalent to Pioglitazone...........................................15 mg.
Glimepiride I.P.............................................................1 mg.
Excipients ………………………………………………….q.s.
Colour : Yellow Oxide of Iron

POZITIV-G 2 ™

Each uncoated tablet contains:
Pioglitazone Hydrochloride I.P.
equivalent to Pioglitazone...........................................15 mg.
Glimepiride I.P.............................................................2 mg.
Excipients ………………………………………………….q.s.
Colour : Red Oxide of Iron